TWST Stock Cash Flow Statements

Twist Bioscience Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Twist Bioscience Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

operating activities
net income	20,390,000	-39,328,000	-31,594,000	-34,655,000	-85,571,000	-45,492,000	-43,008,000	-46,243,000	-57,395,000	-59,156,000	-41,824,000	-51,115,000	-60,517,000	-60,668,000	-45,563,000	-41,242,000	-40,037,000	-37,919,000	-32,900,000	-24,318,000	-28,207,000	-31,768,000	-55,638,000	-31,181,000	-27,916,000	-25,933,000	-22,639,000
adjustments to reconcile net income to net cash from operating activities
depreciation and amortization expense
impairment of long-lived assets				0
stock-based compensation expense
gain on sale of business
other non-cash adjustments	1,152,000	831,000	-20,000	1,179,000	-478,000
changes in assets and liabilities:
accounts receivable, net [1]
inventories	-5,078,000	2,657,000	560,000	4,408,000	1,891,000	486,000	1,201,000	4,289,000	3,555,000	4,675,000	-5,281,000	3,701,000	1,550,000	-4,351,000	-8,436,000	-10,575,000	-5,370,000	-2,422,000	-1,122,000	875,000	-2,398,000	-3,347,000	-86,000	-1,834,000	-1,047,000
prepaid expenses and other current assets [2]
other non-current assets	19,000	-266,000	-356,000	-41,000	163,000	9,000	300,000	326,000	-156,000	707,000	499,000	444,000	2,956,000	642,000	3,231,000	-2,320,000	-2,246,000	-146,000	59,000	-130,000	-228,000	-258,000	62,000	-1,622,000	-251,000	201,000	-392,000
accounts payable	3,194,000	711,000	5,711,000	-4,878,000	-1,202,000	-1,520,000	-4,205,000	1,923,000	-220,000	-7,493,000	3,282,000	6,917,000	1,228,000	-757,000	-5,000	3,348,000	1,396,000	339,000	3,459,000	-1,691,000	-740,000	-2,519,000	-556,000	3,374,000	1,921,000	-1,302,000	-715,000
accrued expenses	158,000	139,000	3,137,000	283,000	273,000	959,000	2,900,000	1,300,000	-1,615,000	4,147,000	-1,254,000	1,661,000	-1,277,000	1,440,000	445,000	1,569,000	1,591,000	104,000	-149,000	714,000	-325,000	-1,758,000	-1,279,000	2,249,000	1,303,000	619,000	39,000
accrued compensation	3,966,000	3,192,000	-11,850,000	1,943,000	6,471,000	4,539,000	-5,078,000	-1,447,000	3,050,000	1,014,000	-3,716,000	-667,000	6,172,000	2,971,000	-3,624,000	2,804,000	4,626,000	3,319,000	-3,357,000	3,633,000	2,680,000	-219,000	-1,629,000
other liabilities[3]
net cash from operating activities	-1,400,000	-12,986,000	-21,428,000	-15,320,000	-6,378,000	-19,423,000	-22,973,000	-20,704,000	-23,412,000	-44,288,000	-54,070,000	-1,267,000	-34,125,000	-42,340,000	-46,653,000	-34,803,000	-27,960,000	-24,549,000	-24,932,000	-25,202,000	-23,468,000	-58,671,000	-34,914,000	-23,358,000	-22,082,000	-20,813,000	-21,684,000
capex	-9,165,000	-4,144,000	-2,268,000	-2,002,000	-965,000	-603,000	-1,506,000	-2,393,000	-4,509,000	-9,053,000	-11,824,000	-16,462,000	-40,642,000	-31,970,000	-12,783,000	-8,089,000	-6,942,000	-8,401,000	-3,629,000	-2,225,000	-2,848,000	-2,737,000	-2,058,000	-3,893,000	-5,172,000	-3,770,000	-1,922,000
free cash flows	-10,565,000	-17,130,000	-23,696,000	-17,322,000	-7,343,000	-20,026,000	-24,479,000	-23,097,000	-27,921,000	-53,341,000	-65,894,000	-17,729,000	-74,767,000	-74,310,000	-59,436,000	-42,892,000	-34,902,000	-32,950,000	-28,561,000	-27,427,000	-26,316,000	-61,408,000	-36,972,000	-27,251,000	-27,254,000	-24,583,000	-23,606,000
investing activities
purchases of property and equipment	-9,165,000	-4,144,000	-2,268,000	-2,002,000	-965,000	-603,000	-1,506,000	-2,393,000	-4,509,000	-9,053,000	-11,824,000	-16,462,000	-40,642,000	-31,970,000	-12,783,000	-8,089,000	-6,942,000	-8,401,000	-3,629,000	-2,225,000	-2,848,000	-2,737,000	-2,058,000	-3,893,000	-5,172,000	-3,770,000	-1,922,000
purchases of investments	-2,732,000	-4,932,000	-20,593,000	-21,193,000	-1,746,000	-10,637,000	-18,329,000	-18,090,000	-7,821,000	-27,787,000	-22,647,000	0	0	0	-217,639,000	0	0	15,497,000	-74,292,000	-92,444,000	-103,901,000	0	-6,537,000	-40,310,000	-50,639,000	-22,790,000	-63,835,000
proceeds from maturity of investments	0	7,650,000	21,325,000	21,910,000	2,000,000	6,000,000	24,000,000	18,236,000	31,000,000	78,000,000	27,500,000	25,000,000	44,805,000	18,676,000	12,000,000	32,000,000	112,000,000	66,494,000	32,000,000		45,600,000	31,500,000	21,000,000		33,100,000
proceeds from sale of business
net cash from investing activities	-9,397,000	-1,426,000	-1,536,000	-1,285,000	-711,000	-5,240,000	4,165,000	-2,247,000	18,670,000	41,160,000	-6,971,000	2,783,000	4,163,000	-13,294,000	-226,582,000	23,911,000	104,575,000			-94,669,000	-61,149,000	28,763,000	12,405,000	-1,187,000	-22,706,000	-15,160,000	-65,757,000
financing activities
proceeds from exercise of stock options	1,829,000	772,000	2,950,000	1,917,000	2,915,000	1,317,000	951,000	171,000	353,000	251,000	604,000	1,250,000	764,000	895,000	3,105,000	2,873,000	2,570,000	3,032,000	6,084,000	5,518,000	1,916,000	1,387,000	1,674,000
proceeds from the issuance of liability related to sale of future revenue	0	0	15,000,000
proceeds from issuance of common stock under employee stock purchase plan	0				0				0				-1,000				0				0
repurchases of common stock for income tax withholding	-3,000	-5,000	-6,000	-8,000	-7,000	-1,536,000	-2,424,000	-1,130,000	-1,014,000	-1,262,000	-999,000	-1,624,000	-2,080,000	-1,492,000	-2,558,000	-2,622,000	-2,476,000	-3,341,000	-2,410,000	-773,000	-450,000	-390,000	-808,000
net cash from financing activities	1,826,000	3,196,000	17,944,000	3,627,000	2,908,000	1,828,000	-1,473,000	442,000	-661,000	1,525,000	-395,000	1,240,000	-1,311,000	271,616,000	-1,011,000	1,575,000	-765,000	1,451,000	326,921,000	5,574,000	108,064,000	188,037,000	2,057,000	2,928,000	84,285,000	-1,634,000	72,999,000
effect of exchange rates on cash, cash equivalents and restricted cash	-71,000	104,000	-53,000	73,000	2,000	-65,000	116,000	-48,000	-320,000	73,000	268,000	-318,000	-105,000	21,000	83,000	-133,000	100,000	48,000	5,000	27,000	12,000	-27,000	9,000
net decrease in cash, cash equivalents, and restricted cash	-9,042,000	-11,112,000	-5,073,000		-4,179,000	-22,900,000	-20,165,000			-1,530,000	-61,168,000												-20,443,000				-14,442,000
cash, cash equivalents, and restricted cash at beginning of period	0	0	229,132,000		0	0	289,281,000		0	0	380,259,000		0	0	467,359,000		0	0	94,246,000		0	0	47,398,000		0	0	81,537,000
cash, cash equivalents, and restricted cash at end of period	-9,042,000	-11,112,000	224,059,000		-4,179,000	-22,900,000	269,116,000		-5,723,000	-1,530,000	319,091,000		-31,378,000	216,003,000	193,196,000		75,950,000	50,540,000	350,319,000		23,459,000	158,102,000	26,955,000		39,497,000	-37,607,000	67,095,000
depreciation and amortization		6,404,000	6,380,000	6,656,000	8,301,000	8,304,000	8,171,000	8,500,000	8,490,000	7,028,000	5,292,000	4,952,000	4,444,000	3,968,000	3,150,000	2,431,000	2,744,000	2,464,000	2,111,000	1,889,000	1,724,000	1,559,000	1,505,000	1,489,000	1,587,000	1,563,000	1,472,000
stock-based compensation		20,328,000	11,991,000	12,347,000	13,734,000	13,824,000	11,020,000	11,747,000	10,597,000	10,259,000	-2,325,000	19,048,000	20,043,000	22,465,000	18,108,000	9,247,000	9,176,000	11,553,000	7,022,000	5,131,000	4,071,000	4,197,000	3,697,000	3,363,000	3,032,000	2,911,000	1,864,000
accounts receivable		-10,722,000	-4,537,000	-2,954,000	3,997,000	-657,000	8,058,000	-1,812,000	5,542,000	-3,952,000	-4,098,000	662,000	-6,439,000	-1,813,000	-2,032,000	-290,000	-581,000	-2,215,000	884,000	-13,029,000	1,484,000	-1,777,000	-950,000	-577,000	-3,529,000	-1,020,000	-1,559,000
prepaid expenses and other current assets		1,133,000	-249,000	567,000	235,000	696,000	-1,116,000	-2,231,000	-344,000	-414,000	-1,177,000	185,000	-1,329,000	-1,316,000	-91,000	-441,000	1,114,000	-688,000	-2,043,000	31,000	-1,761,000	964,000	-2,917,000	868,000	609,000	-365,000	-366,000
other liabilities		1,935,000	-601,000	-468,000	734,000	-1,055,000	-1,528,000	-1,907,000	2,203,000	-530,000	126,000	-10,378,000	2,122,000	866,000	-34,000	1,919,000	-3,073,000	449,000	677,000	1,402,000	1,177,000	-790,000	189,000	108,000	-102,000	-388,000	135,000
supplemental disclosure of cash flow information
income taxes paid, net of refunds		13,000	3,000	-19,000	24,000	299,000	40,000	179,000	104,000	85,000	52,000	116,000	0	39,000	91,000	54,000	46,000	-80,000	81,000	52,000	0	76,000	44,000	70,000	60,000	108,000	53,000
non-cash investing and financing activities
property and equipment additions included in accounts payable and accrued expenses		-807,000	2,136,000		177,000	-438,000	487,000		-61,000	-2,773,000	4,520,000		-2,175,000	-2,742,000	11,479,000		1,580,000	-1,318,000	1,515,000		-752,000	708,000	66,000		1,087,000	-931,000	1,117,000
property and equipment capitalized acquired through tenant improvement allowance
cash flows from operating activities
cash flows from investing activities
cash flows from financing activities
non-cash lease expense, net of tenant improvement allowance
change in fair value of contingent considerations and holdbacks
gain on deconsolidation of revelar
business acquisition, net of cash acquired												0	0	0	-8,160,000	0
deconsolidation of cash and cash equivalent relating to revelar
proceeds from public offerings, net of underwriting discounts, commissions and offering expenses												-2,000	6,000											0
proceeds from issuance under employee stock purchase plan
repayments of long-term debt												0	0					-834,000	-833,000	-833,000	-833,000	-834,000	-833,000
net increase in cash, cash equivalents and restricted cash
cash, cash equivalents, and restricted cash at beginning of year
cash, cash equivalents, and restricted cash at end of year
interest paid												0	0	0	9,000	22,000	36,000	48,000	61,000	75,000	92,000	125,000	146,000	174,000	192,000	206,000	207,000
property and equipment additions included in accrued expenses and accounts payable
operating lease right-of-use assets obtained in exchange for operating lease liabilities								2,461,000				1,873,000	0	9,071,000	10,423,000	0	33,554,000			0	885,000	0	2,833,000
issuance of common stock in connection with the business acquisition								0	1,768,000			0	0	4,608,000	72,514,000
tenant improvement allowance capitalized in property and equipment				0	0
conversion of convertible notes								0
non-cash lease expense					144,000	255,000	248,000		454,000	332,000	254,000		985,000	435,000	1,174,000	1,199,000	830,000	-34,000	248,000	196,000	-1,012,000	-463,000	236,000
change in fair value of acquisition consideration									-582,000	-1,196,000	-4,135,000
other non cash adjustments							64,000			291,000	287,000
impairment of property and equipment and other assets								3,165,000
deferred tax liability													-132,000	-500,000	-10,545,000
other non cash adjustment
net increase in cash, cash equivalents, and restricted cash													-31,378,000	216,003,000	-274,163,000		75,950,000	50,540,000	256,073,000		23,459,000				39,497,000
proceeds from (repayments of) long-term debt															-1,558,000
loss on disposal of property and equipment																0	0	0	2,000					-13,000	194,000	0	8,000
discount (premium) accretion on investment securities																92,000	187,000
realized gain on investments																0	-1,000
allowance for doubtful accounts
non-cash interest expense												0	0	0	3,000	9,000	14,000	19,000	25,000	30,000	35,000	41,000	46,000	51,000	57,000	61,000	64,000
amortization of debt discount												0	0	0	4,000	11,000	17,000	23,000	30,000	36,000	43,000	49,000	56,000	63,000	67,000	74,000	78,000
write off property and equipment												0	0
discount accretion on investment securities													266,000	472,000	318,000				122,000	29,000	-11,000	-82,000	-150,000	-281,000	-447,000
bad debt expense													34,000
contingent consideration and holdbacks
change in fair value of contingent consideration and indemnity holdback															-2,826,000
unrealized currency translation															70,000
deferred offering costs included in accounts payable and accrued expenses																			229,000							-806,000	826,000
proceeds from sale of property and equipment																								16,000
conversion of redeemable convertible preferred stock warrant liability to equity																								0	0	0	631,000
conversion of redeemable convertible preferred stock to common stock																								0	0	0	290,462,000
issuance of common stock in connection with the igenomx acquisition																0
bad debts expense
changes in assets and liabilities, net of acquisition:
proceeds from public offerings, net of underwriting discounts and commissions and offering expenses																	-26,000				107,431,000
repayments of debt
offering expenses included in accounts payable and accrued expenses																					-76,000
accrued litigation settlement																							22,500,000
net cash (used in) / provided by investing activities																			-45,921,000
proceeds from public offering, net of underwriting discounts and commissions and offering expenses																			324,080,000				2,024,000
change in fair value of redeemable convertible preferred stock warrant liability
maturity of investments
proceeds from issuance of series d redeemable convertible preferred stock, net of issuance costs
payments of deferred offering costs
borrowings of long-term debt
fair value of warrants issued in connection with debt
accrued payroll																									2,440,000	2,175,000	-140,000
proceeds from issuance of common stock and exercise of stock options																									864,000	25,000	220,000
principal repayment on long term debt																									-834,000
proceeds from initial public offering, net of underwriting discounts, commissions and offering expenses																										-826,000	72,779,000
changes in assets and liabilities, net of impact of business combination:
inventory																											467,000
change in restricted cash
cash acquired through business combination
net increase in cash and cash equivalents
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
fair value of common stock issued to owners of genome compiler corporation

We provide you with 20 years of cash flow statements for Twist Bioscience stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Twist Bioscience stock. Explore the full financial landscape of Twist Bioscience stock with our expertly curated income statements.

The information provided in this report about Twist Bioscience stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.